http://www.lsis.com/goto/r59/rss 2010-06-23T11:10:29+01:00 text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v59/%3B%97g%FF%11%7E%7F%7D Heidelberg, Germany; April 29 2010: Affimed Therapeutics AG, the therapeutic TandAb antibody company, today announced the successful closing of a Series C financing round of ¬ 20 million. The proceeds from this transaction will be used to fund the clinical validation of Affimed's proprietary therapeutic antibody technology and the ongoing development of its therapeutic antibody pipeline. Affimed's lead program, AFM13 for the treatment of Hodgkin's Lymphoma, is expected to start clinical phase I trials in the third quarter of 2010. AFM11 and AFM12 for the treatment of Non-Hodgkin's Lymphoma, are currently in preclinical development and expected to begin phase I studies in 2011. AFM13 is an (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v59/%3B%97a%F9%1Du%7By 10.03.2010 - In preparation for the clinical entry of its first product candidate Affimed Therapeutics AG expands its development team with an experienced expert. Effective immediately, Dr Christian Hucke takes over responsibility for planning and implementation of the clinical development programs at Affimed. Dr Hucke joins Affimed from Gr nenthal GmbH. Christian Hucke has long-term experience in conception and management of clinical studies. At Gr nenthal he had the overall responsibility for a worldwide Phase-III-Study in pain therapy of cancer patients as well as a Proof-of-Concept-Phase-II-Study against diabetic polyneuropathy. Previously, Dr Hucke worked in clinical drug development (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v59/%3B%97b%FD%14zv%7D Heidelberg, Germany; February 08 2010: Affimed Therapeutics AG, the therapeutic TandAb antibody company, today announced the successful completion of the preclinical development of its lead product AFM 13 for the treatment of Hodgkin's lymphoma. Following promising preclinical data the company is now preparing the start of its first clinical study with AFM 13. Preclinical pharmacology, pharmacokinetic and toxicology data have shown strong evidence for the tolerability and efficacy of AFM 13 to treat Hodgkin's lymphoma. Several studies with cynomolgus monkeys confirmed a good tolerability of the TandAb. No clinical toxicities were observed. During the preclinical development of AFM 13 a (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v59/%3B%97b%FE%17y%7Cz Heidelberg, Germany; January 14 2010: Affimed Therapeutics AG, the therapeutic antibody company from Heidelberg, announced today that it is now concentrating all activities on the exclusive development of its in-house drug candidates derived from the company's proprietary TandAb technology platform. In line with this, the Company has spun-out its antibody discovery activities into a new company: AbCheck s.r.o, (Plzen, Czech Republic). Affimed will now concentrate on preparing the first clinical study for its lead product AFM 13 to treat Hodgkin's lymphoma. The Phase I study for AFM 13 is expected to begin in the first half of 2010. AFM 13 is an innovative bispecific antibody based on the (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v59/%3B%96j%FC%11%7B%7C%7D NEW YORK, Oct. 26 /PRNewswire/ - Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment http:/www.reportlinker.com/p0156557/Reportlinker-Adds-Monoclonal-Antibodies-Pipeline-Analysis-and-Competitive-Assessment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire In the nearly 35 years since the first process for creating mAbs was introduced, they have remained a centerpiece of the growing biotechnology industry. Thirty therapeutic mAbs have been approved around the world, including 23 in the United States. A number of these drugs have attained blockbuster (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v59/%3B%96k%FA%15zx%7F NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Monoclonal Antibody Therapeutics 2009-2024 http:/www.reportlinker.com/p0151198/Reportlinker-Adds-Monoclonal-Antibody-Therapeutics-2009-2024.html Monoclonal Antibody Therapeutics 2009-2024 - market growth, novel technologies and expansion into new therapeutic areas - our new report examines the significant commercial opportunities Monoclonal antibodies achieved total sales of nearly $32bn in 2008 and have grown rapidly to command over 30% of the global biologic drug market. We expect significant opportunities for further commercial growth from 2009 to (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v59/%3B%96k%FE%17yyy Heidelberg, Germany, September 15, 2009 - Affimed Therapeutics AG announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation to the human recombinant antibody AFM13 for the treatment of Hodgkin lymphoma. The designation entitles Affimed to seven-year market exclusivity in the US upon approval of this drug candidate. AFM13 is a novel, bispecific antibody based on Affimed's proprietary TandAb technology. TandAbs are tetravalent antibodies characterized by their ability to identify and selectively destroy tumour cells in the human body by binding target molecules on the surface of tumour cells and activating T-cells or natural killer cells (NK cells) (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v59/%3B%96e%FE%17%7Cxs DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/1d5546/therapeutic_monocl) has announced the addition of the "Therapeutic Monoclonal Antibodies Markets" report to their offering. Newly published Therapeutic Monoclonal Antibodies Markets report that next generation antibodies are forecast to drive the market over the $33 billion mark by 2012. Antibodies are proteins in the immune system that help the body defend against foreign invasion, particularly from pathogens and toxins. As such, a human-engineered therapeutic monoclonal antibody (mAb) is protein derived from the immune system through recombinant DNA technology that has the ability to combine (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v59/%3B%96f%F7%1D%7C%7Br NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Therapeutic Monoclonal Antibodies Markets http:/www.reportlinker.com/p0120329/Reportlinker-Adds-Therapeutic-Monoclonal-Antibodies-Markets.html Antibodies are proteins in the immune system that help the body defend against foreign invasion, particularly from pathogens and toxins. As such, a human-engineered therapeutic monoclonal antibody (mAb) is protein derived from the immune system through recombinant DNA technology that has the ability to combine specifically with a target protein that plays a role in a disease process. With this unique ability to (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v59/%3B%96g%F8%16z%7Er 11.02.2009 - Affimed Therapeutics AG announced the start of a collaboration project with Bayer Schering Pharma AG, the German Cancer Research Center (DKFZ) and other partners within the Molecular Imaging Technology Initiative launched by the German Federal Ministry of Education and Research ("BMBF ). Affimed will receive a funded grant totaling more than 550.000 to carry out its part of the project. BMBF supports the Molecular Imaging Technology Initiative for the development of new diagnostic methods and imaging technologies for clinical use and pharmaceutical applications. Within this collaboration, Affimed will identify and isolate new molecules binding to membrane-associated targets on (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v59/%3B%96g%F8%17u%7By Heidelberg, Germany - February 09, 2009 - Affimed Therapeutics AG, a biopharmaceutical company focused on the development of antibody therapeutics, today announced the start of a collaboration project with Bayer Schering Pharma AG, the German Cancer Research Center (DKFZ) and other partners within the Molecular Imaging Technology Initiative launched by the German Federal Ministry of Education and Research ( œBMBF ). Affimed will receive a funded grant totaling more than ¬550.000 to carry out its part of the project. BMBF supports the Molecular Imaging Technology Initiative for the development of new diagnostic methods and imaging technologies for clinical use and pharmaceutical (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v59/%3B%96a%FD%13x%7Er LONDON, UNITED KINGDOM-(Marketwire - Oct. 6, 2008) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue. Therapeutic Monoclonal Antibodies Report 2008-2023 http:/www.reportlinker.com/p096392/Therapeutic-Monoclonal-Antibodies-Report-2008-2023.html This brand new report investigates the global market for therapeutic monoclonal antibodies. While the pharmaceutical industry as a whole is suffering from single digit growth, thinner pipelines than before and pressure from an ever-aggressive generics industry, the segment of monoclonal antibodies therapeutics is thriving and growing at a double-digit rate. (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v59/%3B%96c%FA%12%7E%7F%7F 10 Jun 2008 - Affimed Therapeutics AG announced that it has appointed Volker Lang, Ph.D., as its Chief Business Officer. Dr. Lang joins Affimed from Scil Technology where he was Vice President of Corporate Development. At Scil Technology, he was responsible for the commercial development of a portfolio of regenerative medicine products including an eye-catching deal with Pfizer earlier this year. In his 16 years experience in the biotechnology sector, spanning basic research, industrial R&D, Business Development & Licensing, and commercial operations & management, Dr. Lang contributed significantly in the scientific development and commercialization of biological agents for industrial and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v59/%3B%96a%FB%15u%7Dr Heidelberg, Germany June 05, 2008 Affimed Therapeutics AG, a biopharmaceutical company focused on the development of antibody therapeutics, today announced that it has appointed Volker Lang, Ph.D., as its Chief Business Officer. Dr. Lang joins Affimed from Scil Technology where he was Vice President of Corporate Development. At Scil Technology, he was responsible for the commercial development of a portfolio of regenerative medicine products including an eye-catching deal with Pfizer earlier this year. In his 16 years experience in the biotechnology sector, spanning basic research, industrial R&D, Business Development & Licensing, and commercial operations & management, Dr. Lang (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v59/%3B%96c%FA%12y%7Fy 14 May 2008 - Affimed Therapeutics AG announced that a collaboration with Dr. Stefan Weiss at the Institute of Biochemistry of the Ludwig Maximilian University in Munich has strongly validated a target for cancer metastases amenable to the development of antibodies or other therapeutic interventions. The target, 37 kDa/67 kDa laminin receptor precursor and/ or its receptor, is overexpressed in cancer cell lines and their metastatic potential correlates with LRP/LR levels. Affimed was able to demonstrate that an antibody targeting this receptor could reduce invasive potential by up to 40% and adhesion by up to 70%. LRP/LR acts as a receptor for prions and viruses, but has also been shown to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v59/%3C%92c%FE%13%7B%7C%7F HEIDELBERG, Germany-(BUSINESS WIRE)-Affimed Therapeutics, AG, a leading developer of next generation antibody therapeutics, today announced a second closing of Euro 5 million to its Series B funding. This addition increases the total for the round to Euro 30 million (USD 45 million) in equity. The capital increase was subscribed by Novo Nordisk A/S via Novo Nordisk Biotech Fund, Novo Nordisk s internal corporate venture fund. The money raised in this Series B financing will be used to fund Affimed s proprietary therapeutic antibody programs. Based on its proprietary TandAb tetravalent antibody format the Company will focus specifically on the two clinical lead programs, a TandAb for the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v59/%3C%92c%FF%17%7Dx%7D OSLO, Norway-(BUSINESS WIRE)-The human antibody company, Affitech AS, announced today the appointment of Dr. Sergej Kiprijanov as the Vice President of Discovery Research and Preclinical Development. Joining Affitech at a key stage in the company s growth, Dr. Kiprijanov brings a wealth of experience in the antibody therapeutic field. Previously CSO of Novoplant GmbH, a German plant biotech company developing antibodies for oral applications, Dr. Kiprijanov was also Head of Research with Affimed Therapeutics AG in Heidelberg, Germany, focusing on engineering human antibodies and antibody fragments for cancer indications. Welcoming the appointment, Affitech CEO Dr. Martin Welschof said, Dr. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v59/%3B%96a%FB%1Dzy%7C OSLO, Norway-(BUSINESS WIRE)-The human antibody company, Affitech AS, announced today the appointment of Dr. Sergej Kiprijanov as the Vice President of Discovery Research and Preclinical Development. Joining Affitech at a key stage in the company s growth, Dr. Kiprijanov brings a wealth of experience in the antibody therapeutic field. Previously CSO of Novoplant GmbH, a German plant biotech company developing antibodies for oral applications, Dr. Kiprijanov was also Head of Research with Affimed Therapeutics AG in Heidelberg, Germany, focusing on engineering human antibodies and antibody fragments for cancer indications. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v59/%3C%95a%FE%11y%7C%7D Mol Immunol. 2007 Mar 3; |-| Little M, Kipriyanov S. |-| Affimed Therapeutics AG, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v59/%3C%95a%FE%11%7Fw%7B Interleukin-13 (IL-13) is a T-cell-derived pleiotropic cytokine of particular medical importance because of its critical role in the development of allergic asthma. The effects of IL-13 on its target cells are mediated through a dimeric transmembrane receptor (IL-13R), which shares the IL-4Ralpha subunit with the IL-4R system, but contains as a specific component the IL-13Ralpha1 chain. We have generated a set of single-chain Fv fragments with specific binding capacity to the extracellular domain of the human IL-13Ralpha1 receptor. Bacteriophage clones displaying receptor-binding antibody domains were selected from both naive and synthetic libraries by repetitive panning on recombinant and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v59/%3C%97f%FF%1Ctzs VANCOUVER, British Columbia & SCOTTSDALE, Ariz. & HEIDELBERG, Germany-(BUSINESS WIRE)-April 10, 2006-InNexus Biotechnology, Inc. (TSX.V: IXS)(OTCBB: IXSBF) and Affimed Therapeutics today announced a collaboration utilizing Affimeds antibodies and InNexus SuperAntibody antibody enhancement drug development platform. Under terms of the agreement, the companies will complete feasibility studies and InNexus will have a right to license one of Affimeds antibodies while Affimed will have the right to license SuperAntibody Technology for one antibody. Exercise of rights are expected to trigger payments in the form of licensing fees, milestone payments and sales royalty. This is a unique product (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v59/%3C%96f%FD%17yz%7F BERLIN and HEIDELBERG, Germany, February 14 /PRNewswire/ - ProBioGen, the international cell specialists from Berlin, and Heidelberg based Affimed Therapeutics AG, specializing in the development of recombinant antibodies for the treatment of cancer, announce the execution of a development collaboration. Within the frame of this contract, ProBioGen will develop a high-producing cell-line as well as a production process and procedure with GMP-manufacturing for clinical material for a TandAB, a bi-specific, tetravalent recombinant antibody, from Affimed. Meanwhile, both companies are discussing extending their collaboration to other products. The co-operation between ProBioGen and Affimed (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v59/%3E%97d%F9%16%7C%7D To develop an effective antitumor immunotherapy for B-lineage non-Hodgkin s lymphoma, we constructed a tetravalent tandem diabody (tanDb) specific for both human CD19 (B-cell marker) and CD3 (T-cell antigen). Here, we report the effective killing of malignant primary B cells from patients with B-cell chronic lymphocytic leukemia (B-CLL) by autologous T cells induced by tanDb at very low E:T ratios. Mononuclear cells from patients with B-CLL were cultured with bispecific antibody fragments in either the presence or absence of monospecific anti-CD28 antibody. Use of tetravalent tanDbs caused almost quantitative elimination of malignant B cells from the blood samples of 19 patients and some (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v59/%3E%94k%F9%13y%7F Bispecific single-chain Fv antibodies comprise four covalently linked immunoglobulin variable (V(H) and V(L) domains of two different specificities connected by three linkers. When assembled in the order V(H)(A)-linker(1)-V(L)(B)-linker(2)-V(H)(B)-linker(3)-V(L)(A), the single-chain molecule either folds head-to-tail with the formation of a diabody-like structure, a so-called bispecific single-chain diabody, or forms a homodimer that is twice as large, a so-called tandem diabody. The formation of the tandem diabody is determined by the association of complementary V(H) and V(L) domains located on different polypeptide chains, and depends on the length and probably the amino acid (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v59/7%93b%FA%15%7F Bispecific antibodies are currently in clinical and preclinical development for the treatment of various cancers. Designed to direct and enhance the body s immune response to specific tumors, bispecific antibodies consist of a targeting domain (typically an antibody fragment that binds to a tumor antigen) linked to a triggering arm that is specific for a cell-surface molecule capable of mediating a phagocytic or lytic response by macrophages, natural killer cells, T-cells, or other effector cells. Recent animal studies have confirmed the therapeutic potential of bispecific antibodies; however, results from clinical trials so far have been less promising and have revealed clear limitations (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v59/%3D%97a%F6%1Dz%7Fs The mouse anti-human CD3 monoclonal antibody OKT3 is a potent immunosuppressive agent used in clinical transplantation. However, OKT3 therapy is associated with unpleasant and often serious side effects which appear to result from cytokine release, complement activation and a human anti-mouse antibody (HAMA) response. To decrease these adverse side effects, we constructed antibody fragments comprising OKT3 variable domains without any constant domains. Single-chain Fv (scFv) monomers, dimers and trimers were generated by changing the linker length between the V(H) and V(L) domains. The linkers used were the natural extensions of the V(H) into the C(H)1 domain. The dimeric molecules (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v59/%3D%97c%F6%13%7C%7Cr Various forms of recombinant monoclonal antibodies are being used increasingly, mainly for therapeutic purposes. This review specifically focuses on what is now called antibody engineering, and discusses the generation of chimeric, humanized, and fully human recombinant antibodies, immunoglobulin fragments, and artificial antigen-binding molecules. Since the production of recombinant antibodies is a limiting factor in their availability, and a shortage is expected in the future, different expression systems for recombinant antibodies and transgenic organisms as bioreactors are also discussed, along with their advantages and drawbacks. |-| Mol Biotechnol. 2004 Jan;26(1):39-60. |-| (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v59/%3D%94c%FE%17%7Exx Bispecific single-chain Fv antibodies comprise four covalently linked immunoglobulin variable (VH and VL) domains of two different specificities. Depending on the order of the VH and VL domains and on the length of peptides separating them, the single-chain molecule either forms two single-chain Fv (scFv) modules from the adjacent domains of the same specificity, a so-called scFv-scFv tandem [(scFv)(2)], or folds head-to-tail with the formation of a diabody-like structure, a so-called bispecific single-chain diabody (scBsDb). We generated a number of four-domain constructs composed of the same VH and VL domains specific either for human CD19 or CD3, but arranged in different orders. When (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v59/%3E%95%60%F8%10t%7C Methods Mol Biol. 2003;207:3-25. |-| Kipriyanov SM. |-| Affimed Therapeutics AG, Heidelberg, Germany. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v59/%3E%95f%FD%12%7B%7E Methods Mol Biol. 2003;207:323-33. |-| Kipriyanov SM. |-| Affimed Therapeutics AG, Heidelberg, Germany. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v59/%3D%95c%FF%1Cz%7Ds To target NK cells against non-Hodgkin s lymphoma, we constructed a bispecific diabody (BsDb) with reactivity against both human CD19 and FcgammaRIII (CD16). Bacterially produced CD19 x CD16 BsDb specifically interacted with both CD19(+) and CD16(+) cells and exhibited significantly higher apparent affinity and slower dissociation from the tumor cells than from effector cells. It was able to induce specific lysis of tumor cells in the presence of isolated human NK cells or nonfractionated PBLs. The combination of the CD19 x CD16 BsDb with a previously described CD19 x CD3 BsDb and CD28 costimulation significantly increased the lytic potential of human PBLs. Treatment of SCID mice bearing (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v59/%3D%95b%FC%17%7Bxs Methods Mol Biol. 2002;178:333-41. |-| Kipriyanov SM. |-| Affimed Therapeutics AG, Ladenburg, Germany. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v59/%3D%95b%FC%12%7Ev%7C Methods Mol Biol. 2002;178:317-31. |-| Kipriyanov SM. |-| Affimed Therapeutics AG, Ladenburg, Germany.